Novartis India Share Price

Novartis is a global healthcare company based in Switzerland, specializing in innovative pharmaceuticals and generics. The company focuses on research and development to deliver effective treatments across various therapeutic areas, including oncology, cardiology, and neuroscience, improving patient outcomes worldwide.

Novartis India has an operating revenue of Rs. 345.10 Cr. on a trailing 12-month basis. An annual revenue de-growth of -9% needs improvement, Pre-tax margin of 37% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -12% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 53 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.